Transplantation therapies have revolutionized care for patients with
end-stage organ (kidney, liver, heart, lung, and pancreatic β-cell) failure,
yet significant problems persist with treatments designed to prevent graft
rejection. Antirejection therapies are not always effective, must be taken
daily, and are both expensive and associated with well-known toxic effects.
Recent advances have suggested that the immune system has more self-regulatory
capability than previously appreciated. In this review, we discuss immune
system function and new therapeutic agents that modify so-called costimulatory
receptor signaling to support transplant function without generally suppressing
the immune system.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 48
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.